On 22 March 2024, SpinChip Diagnostics ASA (“SpinChip” or the “Company”) announced the successful completion of a private placement, raising gross proceeds of NOK 145 million. The financing round was led by bioMérieux, a world leader in the field of in vitro diagnostics, with its NOK 115 million investment.
The net proceeds from the private placement will be used to further advance SpinChip’s proprietary point-of-care (POC) in vitro diagnostics platform, prepare for a CE mark in 2025, and for general corporate purposes.
ABGSC acted as joint bookrunner to the Company, and would like to extend its gratitude to the Company for the vote of confidence.
Contact
Kristian B. Fyksen
Head of Investment Banking and CEO ABGSC Norway
Kristian.Fyksen@abgsc.no +47 48 01 61 52